Can a weight-loss shot also protect your heart?
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A medicine called semaglutide helps people lose weight and also lowers the chance of heart attacks and strokes—even if they don’t have diabetes.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 51 / 5
Evidence Score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A medicine called semaglutide helps people lose weight and also lowers the chance of heart attacks and strokes—even if they don’t have diabetes.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 51 / 5
Evidence Score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Publication
Authors
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH, SELECT Trial Investigators
Related Content
Claims (6)
In people who are overweight or obese but do not have diabetes, the medication semaglutide lowers the risk of serious heart-related events such as heart attack or stroke, and this benefit occurs even when some of the effect is not due to weight loss.
For adults with obesity and heart disease but no diabetes, a weekly injection of semaglutide at 2.4 mg lowers the chance of serious heart problems like heart attack or stroke by 20% over about 3.3 years, regardless of how much weight is lost.
In obese adults with heart disease but no diabetes, taking a weekly 2.4 mg dose of semaglutide was linked to an average treatment duration of 34.2 months and follow-up of 39.8 months in clinical trials.
In obese adults with existing heart disease but no diabetes, a weekly injection of semaglutide at 2.4 mg is associated with a lower rate of serious heart-related events such as heart attack or stroke.
In adults over 45 with heart disease and obesity but no diabetes, a weekly injection of semaglutide at 2.4 mg for about 3.3 years lowers the combined risk of heart-related death, heart attack, or stroke compared to a placebo.